Muscarinic Acetylcholine Receptor M1 Antagonists - Pipeline Insight, 2024

This “Muscarinic Acetylcholine Receptor M1 Antagonists- Pipeline Insight, 2024” report provides comprehensive insights about 5+ companies and 8+ pipeline drugs in Muscarinic Acetylcholine Receptor M1 Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Muscarinic Acetylcholine Receptor M1 Antagonists: Understanding

Muscarinic Acetylcholine Receptor M1 Antagonists: Overview

Muscarinic acetylcholine receptor M1 (M1 mAChR) antagonists are a class of drugs that block the action of acetylcholine at the M1 subtype of muscarinic receptors. These receptors are part of the G-protein coupled receptor family and are predominantly found in the central nervous system, particularly in areas involved in cognitive function such as the cerebral cortex and hippocampus. M1 receptors play a critical role in modulating neurotransmission, influencing processes such as memory, learning, and attention.

Muscarinic acetylcholine receptor M1 antagonists typically contain several structural features essential for their activity. These include aromatic rings, which are crucial for binding to the receptor, and tertiary amines, which contribute to the molecule's basicity and ability to form ionic interactions with the receptor. They also often have linkages, such as ester or ether bonds, connecting different parts of the molecule, influencing pharmacokinetics and binding properties. Some M1 antagonists feature bicyclic or tricyclic ring systems, enhancing their ability to fit into the receptor's binding site. Examples include pirenzepine, dicyclomine, and biperiden, each showcasing variations of these common structural elements.

M1 mAChR antagonists work by binding to the M1 receptor and preventing acetylcholine from activating it. This blockade can alter neurotransmitter release and neuronal excitability, leading to various physiological and behavioral effects. Since M1 receptors are implicated in cognitive processes, their antagonists can impact memory and learning. However, the exact outcomes depend on the specific antagonist and the context in which it is used.

M1 mAChR antagonists have potential therapeutic applications, including treating neurological disorders like Alzheimer's disease, serving as adjunct therapy in schizophrenia, and managing gastrointestinal conditions such as peptic ulcers and irritable bowel syndrome. However, their use is limited due to the broad distribution of muscarinic receptors and potential side effects.

Examples of M1 mAChR Antagonists Some known M1 antagonists include

Pirenzepine: Primarily used in the treatment of peptic ulcers due to its ability to

reduce gastric acid secretion.

Dicyclomine: Used to treat irritable bowel syndrome by reducing muscle spasms in th

e gastrointestinal tract.

Biperiden: Sometimes used in the treatment of Parkinson's disease and drug-induce

d extrapyramidal symptoms.Ongoing research aims to develop more selective M1 antagonists that minimize side effects by targeting the receptors more precisely. This selectivity could enhance therapeutic efficacy for specific conditions while reducing unwanted actions on other muscarinic receptors. Research on Muscarinic Acetylcholine Receptor M1 (M1 mAChR) antagonists is focused on developing more selective compounds to minimize side effects and enhance therapeutic efficacy.

Advances in genetic and molecular biology techniques are aiding in the identification of new drug targets and mechanisms. Future directions include exploring their role in treating cognitive disorders, improving adjunct therapies for psychiatric conditions, and refining their use in gastrointestinal disorders. Ongoing studies aim to balance therapeutic benefits with safety, potentially leading to novel treatments with improved specificity and fewer adverse effects.

"Muscarinic Acetylcholine Receptor M1 Antagonists- Pipeline Insight, 2024" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Muscarinic Acetylcholine Receptor M1 Antagonists pipeline landscape is provided which includes the disease overview and Muscarinic Acetylcholine Receptor M1 Antagonists treatment guidelines. The assessment part of the report embraces, in depth Muscarinic Acetylcholine Receptor M1 Antagonists commercial assessment and clinical assessment of the pipeline products under development.

In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Muscarinic Acetylcholine Receptor M1 Antagonists collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Muscarinic Acetylcholine Receptor M1 Antagonists R&D. The therapies under development are focused on novel approaches to treat/improve Muscarinic Acetylcholine Receptor M1 Antagonists.

Muscarinic Acetylcholine Receptor M1 Antagonists Emerging Drugs Chapters

This segment of the Muscarinic Acetylcholine Receptor M1 Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Muscarinic Acetylcholine Receptor M1 Antagonists Emerging Drugs

TNX-102 SL: Tonix Pharmaceuticals

TNX-102 SL is a patented sublingual tablet formulation of cyclobenzaprine hydrochloride which is designed for daily administration at bedtime with a proposed mechanism of improving sleep quality in fibromyalgia. TNX-102 SL provides rapid trans mucosal absorption and reduced production of a long half-life active metabolite, norcyclobenzaprine, due to bypass of first-pass hepatic metabolism.

As a multifunctional agent with potent binding and antagonist activities at the 5-HT2A-serotonergic, α1-adrenergic, H1-histaminergic, and M1-muscarinic cholinergic receptors. TNX-102 SL is also in development for fibromyalgia-type Long COVID (formally known as post-acute sequelae of COVID-19 [PASC]), alcohol use disorder, and agitation in Alzheimer’s disease. Currently, the drug is in the Phase III stage of its development for the treatment of fibromyalgia.

Muscarinic Acetylcholine Receptor M1 Antagonists: Therapeutic Assessment

This segment of the report provides insights about the different Muscarinic Acetylcholine Receptor M1 Antagonists drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Muscarinic Acetylcholine Receptor M1 Antagonists

There are approx. 5+ key companies which are developing the therapies for Muscarinic Acetylcholine Receptor M1 Antagonists. The companies which have their Muscarinic Acetylcholine Receptor M1 Antagonists drug candidates in the most advanced stage, i.e. Phase III include, Tonix Pharmaceuticals.

Phases

The report covers around 8+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Muscarinic Acetylcholine Receptor M1 Antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Muscarinic Acetylcholine Receptor M1 Antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Muscarinic Acetylcholine Receptor M1 Antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Muscarinic Acetylcholine Receptor M1 Antagonists drugs.

Muscarinic Acetylcholine Receptor M1 Antagonists Report Insights

• Muscarinic Acetylcholine Receptor M1 Antagonists Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Muscarinic Acetylcholine Receptor M1 Antagonists Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Muscarinic Acetylcholine Receptor M1 Antagonists drugs?
• How many Muscarinic Acetylcholine Receptor M1 Antagonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Muscarinic Acetylcholine Receptor M1 Antagonists?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Muscarinic Acetylcholine Receptor M1 Antagonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Muscarinic Acetylcholine Receptor M1 Antagonists and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Tonix Pharmaceuticals
• Bristol Myers Squibb
• WinSanTor, Inc
• Apnimed

Key Products

• TNX-102 SL
• KarXT
• WST-057
• Aroxybutynin/atomoxetine

This product will be delivered within 2 business days.